| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Transcriptional regulator ERG |
|---|
| Ligand | BDBM251906 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | hERG Inhibition Assay |
|---|
| IC50 | >30000±n/a nM |
|---|
| Citation |  Hoveyda, HR; Dutheuil, G; Fraser, GL; Roy, M; Bousmaqui, ME; Batt, F Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof US Patent US10065961 Publication Date 9/4/2018 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Transcriptional regulator ERG |
|---|
| Name: | Transcriptional regulator ERG |
|---|
| Synonyms: | ERG | ERG_HUMAN | Transforming protein ERG |
|---|
| Type: | PROTEIN |
|---|
| Mol. Mass.: | 54615.84 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | ChEMBL_1335569 |
|---|
| Residue: | 486 |
|---|
| Sequence: | MIQTVPDPAAHIKEALSVVSEDQSLFECAYGTPHLAKTEMTASSSSDYGQTSKMSPRVPQ
QDWLSQPPARVTIKMECNPSQVNGSRNSPDECSVAKGGKMVGSPDTVGMNYGSYMEEKHM
PPPNMTTNERRVIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDGKELCKMTK
DDFQRLTPSYNADILLSHLHYLRETPLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPN
TSVYPEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQPSPSTVPKTEDQRPQLDPY
QILGPTSSRLANPGSGQIQLWQFLLELLSDSSNSSCITWEGTNGEFKMTDPDEVARRWGE
RKSKPNMNYDKLSRALRYYYDKNIMTKVHGKRYAYKFDFHGIAQALQPHPPESSLYKYPS
DLPYMGSYHAHPQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTGGIYPNTRLPTSHMPS
HLGTYY
|
|
|
|---|
| BDBM251906 |
|---|
| n/a |
|---|
| Name | BDBM251906 |
|---|
| Synonyms: | US10065961, Compound 4 | US10683295, Compound 4 | US10941151, Compound 4 | US9475814, 4 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C20H14F3N5OS2 |
|---|
| Mol. Mass. | 461.483 |
|---|
| SMILES | FC(F)(F)c1nc(cs1)-c1nnc2CN(CCn12)C(=O)c1ccc(cc1)-c1cccs1 |
|---|
| Structure | 
|
|---|
Search and Browse
